Orano Med receives award at the “Trophées de la HealthTech” event for its promising advances

Orano Med, an Orano subsidiary specialized in nuclear medicine, was awarded the Biotech Prize at the “Trophées de la HealthTech” event held on Monday 27 March, in the presence of Roland Lescure, Minister Delegate in charge of Industry.

Organized by France Biotech, an association of healthcare innovation entrepreneurs, “Trophées de la HealthTech” honors biotech, medtech, and e-health companies whose performance has stood out in the past two years, with advances in R&D, operational development, and partnerships. There were more than 100 candidates in seven categories.

Orano Med is developing a new generation of targeted therapies against cancer using the unique properties of lead-212, a radioactive element with very promising therapeutic characteristics. This “targeted alphatherapy” approach opens new avenues for patients with unmet needs.

Orano Med’s development has accelerated these past two years. In terms of clinical research, based on the promising phase 1 efficacy results, Orano Med launched a phase 2 clinical trial for its most advanced medication: AlphMedix. In parallel, a phase 1 trial has started for a second medication and the preclinical portfolio has further expanded. Orano Med also made progress in its industrial development to prepare for producing and distributing the treatments around the world. The Maurice Tubiana Laboratory (at Bessines-sur-Gartempe in central France), where the full lead-212 production process has been optimized to reach industrial maturity, was once again expanded. Finally, the construction of the first pharmaceutical laboratory for manufacturing and distributing treatments began in the United States and a similar French facility is in the project stage.

Orano Med aims to market the first targeted alphatherapy and build industrial facilities in France that would be the first of their type in the world to manufacture and distribute this treatment.

Julien Dodet, CEO of Orano Med, stated, “We are delighted to have received this prize, a first for Orano Med. It shows that the biotech ecosystem trusts us and recognizes our advances in developing the first targeted alphatherapy against cancer. It’s also testimony to the hard work and commitment of Orano Med’s teams, who are to be congratulated!”

Learn more about Orano Med